What's Happening?
Incyte has announced the acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront, with an additional $750 million contingent on sales milestones. This acquisition includes Vega's lead drug candidate, VGA039, a protein
S modulator currently in phase 3 trials for von Willebrand disease (VWD), a common inherited bleeding disorder affecting approximately 135,000 people in the U.S. The deal marks Incyte's first acquisition under CEO Bill Meury, who aims to diversify the company's portfolio beyond its flagship drug, Jakafi, which faces patent expiration in 2028. VGA039 is positioned as a potential first-in-class subcutaneous prophylactic therapy for VWD, offering an alternative to the current intravenous treatments required multiple times a week.
Why It's Important?
This acquisition is significant for Incyte as it seeks to reduce its dependency on Jakafi, which currently contributes a substantial portion of its revenue. By acquiring VGA039, Incyte aims to establish a stronger foothold in the hematology market, addressing a significant unmet need for VWD patients. The potential market for VGA039 is estimated to exceed $1 billion, highlighting the strategic importance of this acquisition in expanding Incyte's growth prospects. The deal also reflects a broader trend in the pharmaceutical industry towards acquiring late-stage assets to mitigate risks associated with drug development.
What's Next?
The acquisition is expected to close in the third quarter, with Incyte focusing on advancing VGA039 through its phase 3 trials. The company anticipates that successful trial results could significantly expand the use of prophylactic treatments for VWD, potentially increasing the treated patient population. Incyte's strategic move may prompt other pharmaceutical companies to pursue similar acquisitions to bolster their portfolios, particularly in areas with high unmet medical needs.
